Filters: keyword is Antiparkinson Agents [Clear All Filters]
- 2008
The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments,
J Pharmacol Toxicol Methods, vol. 57, no. 2, pp. 114-30. DOI
- 2004
Transdermal iontophoresis of rotigotine across human stratum corneum in vitro: influence of pH and NaCl concentration,
Pharm Res, vol. 21, no. 5, pp. 844-50.
- 2001
Lontophoretic delivery of apomorphine in vitro: physicochemic considerations,
Pharm Res, vol. 18, no. 11, pp. 1509-13.
- 1999
Future delivery systems for apomorphine in patients with Parkinson's disease,
Adv Neurol, vol. 80, pp. 535-44.
- 1998
Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease,
Clin Neuropharmacol, vol. 21, no. 3, pp. 159-68.
Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease,
Clin Neuropharmacol, vol. 21, no. 3, pp. 152-8.
- 1997
Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease,
J Chromatogr B Biomed Sci Appl, vol. 702, no. 1-2, pp. 131-41.
Iontophoretic delivery of apomorphine. I: In vitro optimization and validation,
Pharm Res, vol. 14, no. 12, pp. 1798-803.
Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease,
Pharm Res, vol. 14, no. 12, pp. 1804-10.
- 1996
A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease,
Mov Disord, vol. 11, no. 6, pp. 633-8. DOI
- 1995
Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories,
Mov Disord, vol. 10, no. 4, pp. 433-9. DOI


